17:37 , Sep 21, 2018 |  BC Week In Review  |  Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and...
13:46 , Sep 20, 2018 |  BC Extra  |  Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator of transcription...
19:41 , Apr 14, 2017 |  BC Week In Review  |  Company News

Immune-Onc, University of Texas deal

The centers granted Immune-Onc exclusive, global rights to develop and commercialize biotherapeutics that Immune-Onc says have applications in cancer immunotherapy and other diseases. Additionally, Immune-Onc entered into a multi-year research collaboration with both centers to...
20:46 , Dec 15, 2016 |  BC Innovations  |  Targets & Mechanisms

Keeping the Gas off AXL

With its development of an AXL decoy able to trap and sequester the native receptor’s ligand with femtomolar affinity, Aravive Biologics Inc. believes it has a biologic that can bypass the potency and selectivity issues...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Pelican, Cancer Prevention & Research Institute of Texas cancer news

CPRIT awarded Pelican a $15.3 million New Company Product Development Award to develop agonists directed at tumor necrosis factor (TNF) receptor superfamily member 25 ( TNFRSF25 ; DR3 ; LARD; TRAMP; WSL-1 ) to treat...
07:00 , Apr 14, 2016 |  BC Innovations  |  Strategy

Next stop: Houston

Last month's opening by Johnson & Johnson of the Houston-based JLABS incubator is being seen as a coup by local leaders hoping to make the city the "third coast" of biotech. But stakeholders inside and...
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

Aeglea, Mirna, Cancer Prevention & Research Institute of Texas (CPRIT) cancer news

CPRIT awarded three-year grants totaling up to about $45 million to cancer companies Mirna and Aeglea. Mirna will receive up to $25.1 million to develop compounds that mimic naturally occurring tumor suppressor microRNAs. The company's...
07:00 , Mar 20, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

At least $440 million in new support for public-private partnerships was allocated last month globally. Almost $230 million of that amount is earmarked for the NIH 's Accelerating Medicines Partnership 1 ( see "Selected public-private...
08:00 , Mar 3, 2014 |  BioCentury  |  Emerging Company Profile

CBS: Sniffing out cancer therapy

CBS Therapeutics Inc. is developing first-in-class inhibitors of cystathionine beta synthase that could synergize with existing therapies to treat both KRAS-mutant and wild-type metastatic colorectal cancer. Cystathionine beta synthase (CBS) is found in many cell...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Cancer Prevention & Research Institute of Texas (CPRIT) cancer news

Former CPRIT Chief Commercialization Officer Jerald Cobbs was indicted by a grand jury in Travis County, Texas, related to his handling of an $11 million grant from CPRIT to Peloton Therapeutics Inc. (Dallas, Texas). The...